Welcome to our dedicated page for Nurix Therapeutics SEC filings (Ticker: NRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Buried inside Nurix Therapeutics’ dense biotechnology filings are clues about BTK degrader trial costs, CBL-B inhibitor milestones, and partnership revenue streams. For many, decoding a 300-page report feels impossible. That’s why this page goes beyond a simple document list.
Stock Titan’s AI reads every Nurix Therapeutics annual report 10-K simplified, quarterly earnings report 10-Q filing, and 8-K material events explained the moment they hit EDGAR. Our technology highlights how R&D spending shifts with each clinical phase and pinpoints collaboration payments that can move the stock before earnings day.
Need to track real-time insider sentiment? The platform flags Nurix Therapeutics insider trading Form 4 transactions within minutes, offering context on executive stock transactions Form 4 and historical buying patterns. Curious about governance? Quickly surface board pay details from the Nurix Therapeutics proxy statement executive compensation section.
- AI-powered summaries translate accounting jargon into plain English, answering “understanding Nurix Therapeutics SEC documents with AI.”
- Custom alerts deliver Nurix Therapeutics Form 4 insider transactions real-time so you never miss a crucial trade.
- Interactive charts provide Nurix Therapeutics earnings report filing analysis across quarters.
Whether you’re scanning a single footnote or benchmarking pipeline spend, you’ll find Nurix Therapeutics SEC filings explained simply—complete, current, and immediately actionable.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) – Fiscal Q2 2025 10-Q highlights
- Revenue inflection: Total Q2 revenue jumped to $44.1 million (up 264% YoY) driven by a $30 million license fee from Sanofi and higher collaboration revenue from existing partnerships with Sanofi, Gilead and Pfizer.
- Operating costs accelerate: R&D expense expanded 60% YoY to $78.1 million as the company advanced clinical programs (NX-5948, NX-2127, NX-1607) and DAC discovery work; G&A rose 22% to $14.3 million.
- Loss narrows modestly for the quarter: Net loss was $43.5 million (-$0.52 per share) versus $44.5 million (-$0.71) a year ago, helped by the one-time license payment and a larger share count. For the six-month period, however, the loss widened to $99.8 million.
- Cash runway: Cash, cash equivalents and marketable securities totaled $485.8 million at 31 May 2025, down from $609.6 million at FY-end. Operating cash burn reached $124.2 million in the first half. Management believes existing liquidity funds operations for at least 12 months.
- Collaboration momentum: • Gilead extended the research term by two years, triggering a $15 million payment.
• Sanofi exercised two target license options, providing $30 million.
• Pfizer collaboration produced $10 million in research milestones to date. - Equity activity: 76.4 million shares outstanding after ATM issuances; stockholders’ equity fell to $447.6 million from $527.0 million on higher deficit.
Overall, Nurix continues to monetize its DEL-AI platform through partner payments while accelerating internal R&D, resulting in higher cash burn and sustained losses.
FAQ
What is the current stock price of Nurix Therapeutics (NRIX)?
What is the market cap of Nurix Therapeutics (NRIX)?
What is the core focus of Nurix Therapeutics?
How does the DELigase platform work?
What therapeutic areas does Nurix target?
What makes Nurix's approach different from traditional therapies?
Who are the key collaborators of Nurix Therapeutics?
What role do BTK degraders play in Nurix's pipeline?
How does Nurix integrate new technologies into its research?
What is the significance of targeting E3 ligases?
